Tag: Clinical
Search News
Study suggests blood test could guide precision treatment in bladder cancer
16th June 2021
A blood test that can detect tiny amounts of circulating cancer DNA may be able to identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery, according to a clinical study led by Professor Tom Powles from Barts Cancer Institute at Queen Mary University of London and Barts Health NHS Trust. The findings from the study, published today in Nature, may change our understanding of cancer care following surgery.
Read more
Screening for ovarian cancer did not reduce deaths
13th May 2021
A large-scale randomised trial of annual screening for ovarian cancer did not succeed in reducing deaths from the disease, despite one of the screening methods tested detecting cancers earlier, according to results published in The Lancet.
Read more
Impact of COVID-19 in patients with HBP conditions in East London
12th May 2021
Researchers from Barts Cancer Institute at Queen Mary University of London have conducted a population-based study to explore the risk factors associated with COVID-19 susceptibility and survival in patients with a history of diseases of the liver, pancreas or biliary system – also known as hepato-pancreato-biliary (HPB) diseases – in East London.
Read more
Study to investigate how AI could aid early detection of pancreatic cancer
5th May 2021
Researchers from Barts Cancer Institute at Queen Mary University of London and Edge Hill University are set to investigate how artificial intelligence could be used to improve early diagnosis of pancreatic cancer.
Read more
IBIS-II – new results from international breast cancer study
12th December 2019
The Queen Mary University of London professor leading an international breast cancer study says anastrozole – rather than tamoxifen – should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
Read more
Call for genetic screening for all breast cancer patients
3rd October 2019
A lifetime model evaluating the financial, health and social impact of multigene testing at diagnosis for all breast cancer patients was found to save lives and be extremely cost-effective for both UK and US health systems.
Read more